WHITEHOUSE STATION known as MSD outside the United States and Canada, and Luminex Corporation have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).
[More]
The American Academy of Neurology (AAN), the world's largest professional association of neurologists, is releasing a position paper on how the practice of prescribing drugs to boost cognitive function, or memory and thinking abilities, in healthy children and teens is misguided.
[More]
In the British Medical Journal, concepts about head injuries in sports are now being turned upside down by a group of researchers at Umeå University: Impaired brain function is rather a risk factor for incurring such injuries than a result of them.
[More]
Cognitive impairments are disabling for individuals with schizophrenia, and no satisfactory treatments currently exist. These impairments affect a wide range of cognition, including memory, attention, verbal and motor skills, and IQ.
[More]
Concussions can occur in sports and in combat, but health experts do not know precisely which jolts, collisions and awkward head movements during these activities pose the greatest risks to the brain. To find out, Johns Hopkins engineers have developed a powerful new computer-based process that helps identify the dangerous conditions that lead to concussion-related brain injuries.
[More]
A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.
[More]
Researchers at Karolinska Institutet in Sweden have found an explanation for why the level of kynurenic acid (KYNA) is higher in the brains of people with schizophrenia or bipolar disease with psychosis. The study, which is published in the scientific periodical Molecular Psychiatry, identifies a gene variant associated with an increased production of KYNA.
[More]
Researchers have found an allele in a voltage-gated calcium gene that is associated with an increased risk for poor executive function in patients with bipolar disorder.
[More]
Impaired cognitive function among bipolar disorder patients seems to be stable over time, suggesting it is an enduring feature of the condition, show the results of a longitudinal study.
[More]
Using a shunt with an adjustable Strata valve that is initially set at the highest setting so it can be titrated down is a worthwhile approach to treat idiopathic normal pressure hydrocephalus.
[More]
An element of the event-related potential response to visual stimuli is impaired in patients with prodromal symptoms of schizophrenia, research suggests.
[More]
For older adults looking to sharpen their mental abilities, it might be time to log on to Facebook. Preliminary research findings from the University of Arizona suggest that men and women older than 65 who learn to use Facebook could see a boost in cognitive function.
[More]
Researchers have determined that fibromyalgia prevalence is 2.1% of the general population in Germany. Results appearing in Arthritis Care & Research, a journal published by Wiley on behalf of the American College of Rheumatology (ACR), suggest that fibromyalgia is a spectrum disorder rather than a categorical illness. Additionally, a number of fibromyalgia cases in the general population satisfy proposed criteria for physical symptom disorder—the presence of one or more physical symptoms that impair function, which cannot be explained by another clinical or psychiatric illness.
[More]
Valproate (sodium salt of valproic acid) is an anticonvulsant used in the treatment of epilepsy, migraine and bipolar disorder as well as some other off label psychiatric indications.
[More]
Vigorous activity can improve the physical and mental health of older adults, but for many, particularly Latinos, exercise is not a regular part of their lives, according to a University of Illinois at Chicago researcher.
[More]
This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.
[More]
Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
[More]
Nitric oxide, a gaseous molecule produced in the brain, can damage neurons. When the brain produces too much nitric oxide, it contributes to the severity and progression of stroke and neurodegenerative diseases such as Alzheimer's. Researchers at Sanford-Burnham Medical Research Institute recently discovered that nitric oxide not only damages neurons, it also shuts down the brain's repair mechanisms.
[More]
Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.
[More]
RBC Life Sciences, Inc., has been granted US Patent 8357422, which protects its unique dietary supplement formulation that nutritionally supports cognitive function, learning and remembering. The Company markets this supplement under the name "Neurobright."
[More]